The problem for the wildly overexposed Affleck of the early 2000s was that the attachment of his name to any project was the equivalent of admitting in advance near certain box-office death.
But Robert Meyer, a top official in the office that approves drugs, took a more tempered stance, admitting there were fundamental disagreements at the FDA about what to do with Avandia.